Esperion Therapeutics, Inc. Invites You to Participate in its First Quarter 2001 Conference Call

Apr 17, 2001, 01:00 ET from Esperion Therapeutics, Inc.

    ANN ARBOR, Mich., April 17 /PRNewswire/ -- In conjunction with the release
 of its financial results for the first quarter ended March 31, 2001, Roger S.
 Newton, Ph.D., President and Chief Executive Officer of Esperion Therapeutics,
 Inc. (Nasdaq: ESPR), will conduct a conference call:
 
                            Tuesday, April 24, 2001
                        5:00 p.m. Eastern Daylight Time
                          To participate in this call,
          dial: 877-669-8074 (domestic), 706-634-7276 (international)
                     passcode: Esperion Therapeutics, Inc.
       live webcast:  http://www.esperion.com (click on Media/Investors)
                shortly before 5:00 p.m. Eastern Daylight Time.
 
                               To reserve a line,
                   please call Jacqueline Franchetti at JFCI
                                 516-365-2091.
 
     A replay of the call will be available from 7:00 p.m. EDT, April 24
 through 7:00 p.m., April 26, 2001. The replay number is 800-642-1687
 (domestic), or 706-645-9291 (international) and the replay passcode is 722819.
 You can also hear a replay on the Internet at http://www.esperion.com (click
 on Media/Investors) until May 24th.
 
     Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
 for the treatment of cardiovascular and metabolic diseases.  Esperion intends
 to commercialize a novel class of drugs that focuses on a new treatment
 approach called "HDL Therapy," which is based on the Company's understanding
 of high-density lipoprotein, or HDL, function.  HDL is the primary facilitator
 of the reverse lipid transport, or RLT, pathway.  The RLT pathway is
 responsible for removing excess cholesterol from arteries and other tissues
 and for its transport to the liver for elimination from the body.  The goal of
 Esperion is to develop drugs that exploit the beneficial functions of HDL
 within the RLT pathway.  Esperion currently has five product candidates under
 development for the treatment of cardiovascular and metabolic diseases.
 Esperion successfully completed an initial public offering on August 9, 2000,
 and is listed on the Nasdaq National Market under the symbol "ESPR."
 
     Statements included in this press release that are not historical in
 nature are "forward-looking statements" within the meaning of the Private
 Securities Litigation Reform Act of 1995. These statements often are
 identified by words such as "hope," "intend," "plan," "expects" and similar
 expressions.  We caution readers that our forward-looking statements, which
 speak only as of the date of this press release, are based on management's
 current expectations and involve certain factors, such as risks and
 uncertainties, which may cause our actual results to vary materially from
 results expressed or implied in these forward-looking statements.  These
 factors include, but are not limited to, risks associated with: the progress
 and cost of the development of our products, the extent and timing of market
 acceptance of our products, our dependence on third-parties to conduct
 clinical trials for our products, the extent and timing of regulatory
 approval, as desired or required, for our products, our dependence on
 licensing arrangements and strategic relationships with third parties for the
 research, development, manufacturing and commercialization of our products,
 our dependence on patents and proprietary rights, the Company's procurement,
 maintenance, enforcement and defense of its patents and proprietary rights and
 manufacturing.  More detailed information about these and other factors is set
 forth in the Company's filings with the U.S. Securities and Exchange
 Commission.  The Company undertakes no obligation to publicly update or revise
 any forward-looking statements to reflect new information or future events or
 circumstances.
 
 

SOURCE Esperion Therapeutics, Inc.
    ANN ARBOR, Mich., April 17 /PRNewswire/ -- In conjunction with the release
 of its financial results for the first quarter ended March 31, 2001, Roger S.
 Newton, Ph.D., President and Chief Executive Officer of Esperion Therapeutics,
 Inc. (Nasdaq: ESPR), will conduct a conference call:
 
                            Tuesday, April 24, 2001
                        5:00 p.m. Eastern Daylight Time
                          To participate in this call,
          dial: 877-669-8074 (domestic), 706-634-7276 (international)
                     passcode: Esperion Therapeutics, Inc.
       live webcast:  http://www.esperion.com (click on Media/Investors)
                shortly before 5:00 p.m. Eastern Daylight Time.
 
                               To reserve a line,
                   please call Jacqueline Franchetti at JFCI
                                 516-365-2091.
 
     A replay of the call will be available from 7:00 p.m. EDT, April 24
 through 7:00 p.m., April 26, 2001. The replay number is 800-642-1687
 (domestic), or 706-645-9291 (international) and the replay passcode is 722819.
 You can also hear a replay on the Internet at http://www.esperion.com (click
 on Media/Investors) until May 24th.
 
     Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
 for the treatment of cardiovascular and metabolic diseases.  Esperion intends
 to commercialize a novel class of drugs that focuses on a new treatment
 approach called "HDL Therapy," which is based on the Company's understanding
 of high-density lipoprotein, or HDL, function.  HDL is the primary facilitator
 of the reverse lipid transport, or RLT, pathway.  The RLT pathway is
 responsible for removing excess cholesterol from arteries and other tissues
 and for its transport to the liver for elimination from the body.  The goal of
 Esperion is to develop drugs that exploit the beneficial functions of HDL
 within the RLT pathway.  Esperion currently has five product candidates under
 development for the treatment of cardiovascular and metabolic diseases.
 Esperion successfully completed an initial public offering on August 9, 2000,
 and is listed on the Nasdaq National Market under the symbol "ESPR."
 
     Statements included in this press release that are not historical in
 nature are "forward-looking statements" within the meaning of the Private
 Securities Litigation Reform Act of 1995. These statements often are
 identified by words such as "hope," "intend," "plan," "expects" and similar
 expressions.  We caution readers that our forward-looking statements, which
 speak only as of the date of this press release, are based on management's
 current expectations and involve certain factors, such as risks and
 uncertainties, which may cause our actual results to vary materially from
 results expressed or implied in these forward-looking statements.  These
 factors include, but are not limited to, risks associated with: the progress
 and cost of the development of our products, the extent and timing of market
 acceptance of our products, our dependence on third-parties to conduct
 clinical trials for our products, the extent and timing of regulatory
 approval, as desired or required, for our products, our dependence on
 licensing arrangements and strategic relationships with third parties for the
 research, development, manufacturing and commercialization of our products,
 our dependence on patents and proprietary rights, the Company's procurement,
 maintenance, enforcement and defense of its patents and proprietary rights and
 manufacturing.  More detailed information about these and other factors is set
 forth in the Company's filings with the U.S. Securities and Exchange
 Commission.  The Company undertakes no obligation to publicly update or revise
 any forward-looking statements to reflect new information or future events or
 circumstances.
 
 SOURCE  Esperion Therapeutics, Inc.